Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195197 | 0.83 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL2019493 | 0.82 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL3183147 | 0.81 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL4094266 | 0.79 | RAB9A (0.47) | CHRM3CHRM2CHRM1KMT2A | |
| SCHEMBL2021692 | 0.77 | HSD11B1 (0.64) | EPHX2HSD11B1KMT2A | |
| SCHEMBL2024482 | 0.76 | HSD11B1 (0.45) | EPHX2HSD11B1 | |
| SCHEMBL2019630 | 0.74 | HSD11B1 (0.62) | EPHX2HSD11B1KMT2A | |
| SCHEMBL12586361 | 0.74 | HSD11B1 (0.48) | EPHX2HSD11B1KMT2A | |
| SCHEMBL6093033 | 0.74 | EPHX2 (0.52) | EPHX2HSD11B1 | |
| SCHEMBL3179337 | 0.73 | HSD11B1 (0.54) | EPHX2HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | claimed |
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICAL N.V. (BE) | 2006-04-13 | — | — | US | claimed |
| EP-1581476-A2 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004056745-A2 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | claimed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| EP-1846362-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006074330-A2 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | DHCR7, HSD3B2, HSD3B1 | EPHX2 136/4885HSD11B1 5/4885CHRM3 2034/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | EPHX2 661/4885HSD11B1 1/4885CHRM3 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.